Drug-Conjugated Dendrimer Hydrogel Enables Sustained Drug Release via a Self-Cleaving Mechanism. Mol Pharm 2019 May 06;16(5):1874-1880
Date
04/13/2019Pubmed ID
30974947Pubmed Central ID
PMC10958997DOI
10.1021/acs.molpharmaceut.8b01207Scopus ID
2-s2.0-85065441357 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
In this study, the anticancer drug, camptothecin (CPT), was covalently grafted onto polyamidoamine (PAMAM) dendrimer surface and then reacted with polyethylene glycol diacrylate (PEG-DA) to form dendrimer hydrogel (DH-G3-CPT) with low cross-linking density. In this novel drug delivery system, CPT was cleaved from dendrimer via the ammonolysis of ester bonds and then diffused out of the hydrogel network, thus leading to significantly prolonged drug release. The self-cleaving release kinetics of camptothecin can be further tuned by pH. This DH-G3-CPT drug delivery system has both injectability and sustained drug release. It showed an excellent tumor inhibition effect following intratumoral injection in a head and neck cancer model of mouse.
Author List
Wang J, He H, Cooper RC, Gui Q, Yang HAuthor
Hu Yang PhD Chair, Professor in the Biomedical Engineering department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAntineoplastic Agents, Phytogenic
Camptothecin
Cell Line, Tumor
Cell Survival
Delayed-Action Preparations
Dendrimers
Drug Liberation
Head and Neck Neoplasms
Humans
Hydrogels
Injections
Male
Mice
Mice, Nude
Polyethylene Glycols
Tumor Burden
Xenograft Model Antitumor Assays
